Skip to content

Effect of the Dietary Supplement Taxifolin Aqua on the Recovery Period After COVID-19 Pneumonia

A Prospective, Randomized, Comparative Study in Two Groups to Assess the Effect of the Use of a Dietary Supplement Taxifolin Aqua on the Recovery Period After COVID Pneumonia and on the Biological Age

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04871802
Enrollment
100
Registered
2021-05-04
Start date
2021-05-10
Completion date
2021-10-01
Last updated
2021-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

Objective of the study is to evaluate the effect of Taxifolin Aqua therapy on the indicators of respiratory function, the state of the arterial wall, the contractile function of the myocardium, as well as to assess the effect of Taxifolin Aqua therapy on markers of biological age, quality of patients life.

Detailed description

The study will include 100 patients who had covid pneumonia 3 months ago. If the inclusion / exclusion criteria are met, the patient is asked to sign an informed consent to participate in the study. Consenting patients are randomized to an intervention group or a control group. The control group (n = 50) will receive standard therapy, patients from the intervention group (n = 50) will be prescribed Taxifolin Aqua 30 mg per day in addition to standard therapy. Patients will be randomized to the control and main group using random number spreadsheets, assuming that the control and main groups will be homogeneous in the main demographic and clinical parameters. Patient monitoring will be carried out within 2 months from the date of inclusion. A follow-up visit is scheduled in 2 months. During the study, the patient will be regularly monitored for tolerance and safety of therapy with Taxifolin Aqua.

Interventions

DIETARY_SUPPLEMENTTaxifolin Aqua

Dietary supplement

Sponsors

Pirogov Russian National Research Medical University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Patients of both sexes who had covid pneumonia 3 months ago and signed an informed consent and aged 18+.

Exclusion criteria

Standard contraindications to Taxifolin Aqua use.

Design outcomes

Primary

MeasureTime frameDescription
Dynamics of spirometry indicesIn 2 months after recruitmentspirometry
Dynamics of ECHO CGIn 2 months after recruitmentECHO CG
Dynamics of pulse wave velocityIn 2 months after recruitmentapplanation tonometry
Dynamics of augmentation indexIn 2 months after recruitmentapplanation tonometry

Secondary

MeasureTime frameDescription
Dynamics of biological ageIn 2 months after recruitmentLaboratory indicators

Countries

Russia

Contacts

Primary ContactIrina Strazhesko, MD, PhD
Istrazhesko@gmail.com
Backup ContactOlga Tkacheva, MD, PhD
rgnkc@rgnkc.ru+74991871254

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026